[1] BANGHAM A D,STANDISH M M,WATKINS J C.Diffusion of univalent ions across the lamellae of swollen phospholipids [J].Journal of Molecular Biology,1965,13(1):238-252.
[2] BUDAI M,SZOGYI M.Liposomes as drug carrier systems.Preparation,classification and therapeutic advantages of liposomes [J].Acta Pharmaceutica Hungarica,2001,71(1):114-118.
[3] TORCHILIN V,WEISSIG V.Liposome:A practical approach (Practical approach series)[M].2nd ed.England:Oxford University Press,2003:10-12.
[4] LASIC D D.Liposomes:from physics to applications [M].Netherland:Elsevier Science Publishers,1993:3-7.
[5] LANGSTON M V,RAMPRASAD M P,KARARLI T T,et al.Modulation of the sustained delivery of myelopietin (Leridistim) encapsulated in multivesicular liposomes (Depofoam) [J].Journal of Controlled Release,2003,89(1):87-99.
[6] 赵海霞,郭兴奎,孔德亮,等.脂质体制备技术[J].山东中医药杂志,2000,19(7):435-437.
[7] 陈建雯,马波,林华,等.流感疫苗脂质体干粉制备方法对其免疫原性影响研究[J].南京医科大学学报:自然科学版,2013(7):1019-1023.
[8] 高晶,黄少烈.脂质体的制备方法及其比较[J].中国油脂,2004,29(10):52-54.
[9] 杨文秀.脂质体主动载药的研究与应用进展[J].现代医药卫生,2011,27(17):2647-2648.
[10] ZHIGALTSEV I V,MAURER N,AKHONG Q F,et al.Liposome-encapsulated vincristine,vinblastine and vinorelbine:A comparative study of drug loading and retention [J].Journal of Controlled Release,2005,104(1):103-111.
[11] 高媛媛,张维农.脂质体的制备与检测方法研究进展[J].武汉工业学院学报,2010,29(3):44-52.
[12] 邓意辉,于彬,李焕秋,等.pH梯度法制备阿霉素脂质体[J].沈阳药科大学学报,1997,14(4):239-240.
[13] SANDRA R,ANNA S,GIACOMO M,et al.Synthesis and liposome insertion of a new poly (carboranylalkylthio) porphyrazine to improve potentiality in multiple-approach cancer therapy [J].Journal of the American Chemical Society,2007,129(10):2728-2729.
[14] LI Z,YU L,ZHENG L Q,et al.Studies on crystallinity state of puerarin loaded solid lipid nanoparticles prepared by double emulsion method [J].Journal of Thermal Analysis and Calorimetry,2010,99(2):689-693.
[15] 贾莉,赵辉,刘沛沛.阿霉素脂质体的冻干工艺考察[J].北方药学,2013,10(8):63-64.
[16] MORTAZAVI S M,MOHAMMADABADI M R,KHOSRAVIDARANI K,et al.Preparation of liposomal gene therapy vectors by a scalable method without using volatile solvents or detergents [J].Journal of Biotechnology,2007,129(4):604-613.
[17] GAUR P K,MISHRA S,GUPTA V B,et al.Targeted drug delivery of Rifampicin to the lungs:Formulation,characterization,and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome [J].Drug Development and Industrial Pharmacy,2010,36(6):638-646.
[18] 穆筱梅,梁世强.脂质体的制备方法及其研究进展[J].时珍国医国药,2008,19(7):1784-1786.
[19] 于波涛,张志荣,刘文胜.提高脂质体包封率的方法及其研究进展[J].中国医药工业杂志,2002,33(11):564-568.
[20] 吴芳.脂质体制剂的研究与应用[J].中国医药工业杂志,1999,30(12):564.
[21] 杨莉,成丽,魏于全.脂质体在肿瘤靶向治疗中的应用[J].华西医学,2005,20(2):387-388.
[22] 陆彬.药物新剂型与新技术[M].北京:人民卫生出版社,2005:179.
[23] 曹纯洁.长循环脂质体的研究进展[J].药学实践杂志,2005,23(1):1-3.
[24] 陈静,潘兴国,牛焕义,等.替吉奥胶囊联合奥沙利铂、伊立替康/亚叶酸钙治疗晚期胃癌疗效分析[J].重庆医科大学学报,2011,36(1):1397-1399.
[25] 陈果,彭健,何颖,等.伊立替康长循环脂质体的初步生物学活性研究[J].中国现代医学杂志,2013,23(9):18-22.
[26] VENUGOPALAN P,JAIN S,SANKAR S,et al.pH-sensitive liposomes:mechanism of triggered release to drug and gene delivery prospects [J].Pharmazie,2002,57(10):659-671.
[27] 王潞,赵烽,刘珂.牛蒡子苷及牛蒡子苷元的药理作用研究进展[J].中草药,2008,39(3):467-470.
[28] 武鑫朋,孙李妍,慕宏杰,等.Box-Behnken效应面法优化牛蒡苷pH敏感脂质体处方[J].齐鲁药事,2011,30(11):625-628.
[29] LIU T G,TANG M Z,JIN F G.Thermo-controlled drug-release characteristics and stability of thermo-sensitive liposome of ADM [J].Fourth Mil Med Univ,2002,23:1225-1227.
[30] 杨美燕,李煜蒙,梅兴国.奥沙利铂长循环热敏脂质体的包封率测定及体外释放考察[J].军事医学科学院院刊,2007,31(5):448-450.
[31] 庄宝雄,陈燕铭,张阳德,等.奥沙利铂长循环热敏脂质体的制备与理化性质研究[J].中国现代医学杂志,2011,21(36):4558-4561.
[32] 崔晓波,梁传余.18例原发鼻腔和鼻窦的T/NK淋巴瘤的临床分析[J].临床耳鼻咽喉科杂志,2004,18(11):651-652.
[33] 唐琼兰,刘卫平,李甘地.西南地区鼻和鼻型NK/T细胞淋巴瘤的临床病理特征及预后分析[J].肿瘤,2003,23(5):411-413.
[34] 杨平,林珈好,王玉蓉.盐酸小檗碱前体脂质体的制备及理化性质研究[J].药物研究,2012,2(2):32-33.
[35] 樊祥山.磁性脂质体在肿瘤治疗研究中的应用[J].国外医学:肿瘤学分册,2003,30(2):147-149.
[36] URASAKI Y,LACO G,TAKEBAYASHI Y,et al.Use of camptothecin-resistant mammalian cell activity of the role of topoisomerase in the antiproliferative activity of the indolocarbazole,NB-506,and its topoisomerase binding site [J].Cancer Research,2001,61(2):504.
[37] 凌家俊,古锦辉,谢毅,等.羟基喜树碱磁性脂质体的制备及其靶向性特征试验[J].中国实验方剂学杂志,2012,18(16):19-23.
[38] 何驰,吴婷婷.免疫脂质体在肿瘤治疗中的应用[J].中国肿瘤生物治疗杂志,2012,19(2):215-218.
[39] TAGUCHI T.Review of a new antimetabolic agent 1-hexylcarbamoyl 5-fluorouracil (HCFU) [J].Recent Results in Cancer Research,1980,70:125-132.
[40] 孟胜男,赵希贤,姜翠莲,等.大肠癌特异性卡莫氟免疫脂质体的体外抗癌活性研究[J].沈阳药科大学学报,2003,20(5):370-372.
[41] 王森,欧水平,朱卫丰,等.柔性脂质体在中药经皮给药制剂中的应用[J].中国实验方剂学杂志,2011,17(1):30-34.
[42] 魏向东.氯雷他定致消化道损害1例[C]//2008全国中西医结合皮肤性病学术会议论文汇编.2008:100.
[43] 谢艳萍.氯雷他定柔性脂质体的制备及体外透皮研究[J].中国药师,2012,15(4):445-448. |
